Valerio Therapeutics S.A.
ALVIO.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | 0.07 | -0.01 | 0.01 |
| FCF Yield | -110.73% | -83.92% | -34.78% | -36.58% |
| EV / EBITDA | -1.97 | -1.33 | -1.41 | -2.71 |
| Quality | ||||
| ROIC | -232.20% | -78.33% | -46.34% | -15.02% |
| Gross Margin | 71.39% | 70.39% | 64.38% | 90.94% |
| Cash Conversion Ratio | 0.52 | 0.91 | 0.48 | 1.44 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.51% | -23.76% | -6.69% | -1.79% |
| Free Cash Flow Growth | 31.95% | -89.10% | -14.01% | -81.59% |
| Safety | ||||
| Net Debt / EBITDA | -1.02 | -0.12 | 0.26 | 1.36 |
| Interest Coverage | -52.68 | -307.39 | -7.79 | -6.04 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 88.83 | 0.69 | 0.25 |
| Cash Conversion Cycle | -3,380.66 | -1,294.87 | -1,546.76 | -602.36 |